Edition:
United States

Histogenics Corp (HSGX.OQ)

HSGX.OQ on NASDAQ Stock Exchange Capital Market

0.68USD
4:00pm EDT
Change (% chg)

$0.05 (+8.41%)
Prev Close
$0.63
Open
$0.69
Day's High
$0.74
Day's Low
$0.62
Volume
2,214,170
Avg. Vol
325,732
52-wk High
$3.26
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan
Thursday, 21 Dec 2017 06:00am EST 

Dec 21 (Reuters) - Medinet Co Ltd <2370.T>::HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET.HISTOGENICS - TRANSACTION TERMS INCLUDE A $10 MILLION UP-FRONT PAYMENT WITH A POTENTIAL OF $87 MILLION IN TOTAL MILESTONES, AND TIERED ROYALTIES ON SALES.HISTOGENICS - PLANS TO INITIATE PHASE 3 CLINICAL TRIAL IN JAPAN IN SECOND HALF OF 2018 WITH POTENTIAL COMMERCIALIZATION IN JAPAN IN 2021 FOR NEOCART.  Full Article

MEDINET signs license contract for NeoCart with Histogenics
Thursday, 21 Dec 2017 01:49am EST 

Dec 21 (Reuters) - MEDINET Co Ltd <2370.T> ::Says it entered into a license contract for development and sale of autologous cultured chondrocyte named NeoCart, with Histogenics Corp <<>>.  Full Article

Histogenics Corp announces Q3 loss per share $0.23
Thursday, 9 Nov 2017 06:30am EST 

Nov 9 (Reuters) - Histogenics Corp :Histogenics Corporation announces third quarter 2017 financial and operating results.Q3 loss per share $0.23.Q3 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S.Histogenics Corp - ‍Potential biologics license application filing remain on track for Q3 of 2018​.Histogenics Corp - ‍Believes its current cash position will be sufficient to fund its operations into middle of 2018​.Histogenics - ‍As of September 30, 2017, co had cash, cash equivalents and marketable securities of $12.6 million, compared to $31.9 million at December 31, 2016​.  Full Article

Histogenics says Q2 loss per share $0.25
Thursday, 10 Aug 2017 06:30am EDT 

Aug 10 (Reuters) - Histogenics Corp :Histogenics corporation announces second quarter 2017 financial and operating results.Top-line data, potential BLA filing for neocart phase 3 trial expected in Q3 2018​ .Q2 loss per share $0.25.Q2 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.Of June 30, Histogenics had cash, cash equivalents and marketable securities of $18.5 million, compared to $31.9 million at december 31, 2016​.Histogenics believes its current cash position will be sufficient to fund its operations into middle of 2018​.Completed enrollment in neocart phase 3 clinical trial​.  Full Article

Histogenics on track for top-line one year superiority data, potential BLA filing in Q3 of 2018
Tuesday, 27 Jun 2017 04:01pm EDT 

June 27 (Reuters) - Histogenics Corp ::Histogenics completes enrollment for phase 3 clinical trial of neocart® to treat knee cartilage damage.Histogenics Corp - on track for top-line one year superiority data and potential BLA filing in Q3 of 2018.  Full Article

Histogenics posts Q1 loss per share $0.27
Thursday, 11 May 2017 06:30am EDT 

May 11 (Reuters) - Histogenics Corp :Histogenics Corporation announces first quarter 2017 financial and operating results.Q1 loss per share $0.27.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Histogenics Corp - neocart approval pathway in japan defined after successful conclusion of discussions with Japan Pharmaceuticals and Medical Devices Agency.Histogenics Corp - as of March 31, 2017, had cash, cash equivalents and marketable securities of $24.4 million, compared to $31.9 million at December 31, 2016.  Full Article

Histogenics files for mixed shelf of up to $50 mln
Thursday, 16 Mar 2017 06:30am EDT 

Histogenics Corp :Files for mixed shelf of up to $50 million - sec filing.  Full Article

Histogenics Corporation Q4 loss per share $0.63
Thursday, 16 Mar 2017 06:30am EDT 

Histogenics Corp : Histogenics Corporation announces financial and operating results for the fourth quarter and year ended December 31, 2016 . Histogenics Corp qtrly loss per share $0.63 . Histogenics Corp says financing completed in Q3 of 2016 expected to fund company to phase 3 data . Histogenics Corp - intends to complete raw materials engineering runs in 2017 including generating data for collagen scaffold and proprietary adhesive . Histogenics - at December 31, 2016, had cash, cash equivalents and marketable securities of $31.9 million, compared to $30.9 million at December 31, 2015 . Histogenics - expects total operating expenses of between $25 and $27 million for year ended December 31, 2017 .Histogenics - believes its current cash position will be sufficient to fund its operations into middle of 2018.  Full Article